Paper Details

  1. Home
  2. Paper Details

Ciclesonide: a closer look at its systemic and oropharyngeal safety profile.

Author: BergerWilliam E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ciclesonide, a novel inhaled corticosteroid (ICS), shows promise as a safe and effective treatment for asthma. It has a favorable safety profile with no observed effect on the hypothalamic-pituitary-adrenal (HPA) axis and a low incidence of oropharyngeal adverse events, making it a potential benefit for patients with asthma.
Paper Details　
Original Abstract of the Article :
Inhaled corticosteroids (ICS) are recommended first-line therapy for patients with asthma of all severities. Prolonged exposure to high-dose ICS can cause systemic and oropharyngeal adverse events. Minimizing ICS-related adverse events by selecting an ICS with an improved safety profile may increase...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/157488606777934422

データ提供：米国国立医学図書館（NLM）

Ciclesonide: A Safer Approach to Asthma Treatment

The management of [asthma] requires careful consideration, with patients often needing long-term treatment to control their symptoms. This research explores the safety profile of ciclesonide, a novel inhaled corticosteroid (ICS), in comparison to other ICSs.

The authors highlight ciclesonide's favorable safety profile, demonstrating that it is well tolerated and exhibits a low incidence of oropharyngeal adverse events. Furthermore, ciclesonide was found to have minimal impact on hypothalamic-pituitary-adrenal (HPA)-axis function, a common concern with prolonged ICS use.

A Safer Option for Asthma Management

The study's findings suggest that ciclesonide offers a safer alternative to other ICSs for managing asthma. Its favorable safety profile could lead to improved patient adherence to their treatment regimens, potentially leading to better long-term outcomes.

Optimizing Asthma Treatment

This research underscores the importance of choosing the right ICS for each individual patient. By considering the safety profile and potential side effects of different ICSs, healthcare providers can optimize asthma treatment, minimizing adverse events and improving overall patient well-being.

Dr.Camel's Conclusion

The journey of asthma management can be challenging, requiring careful navigation and a commitment to long-term treatment. This research provides a beacon of hope, highlighting the potential of ciclesonide as a safer and more effective ICS. Like a camel seeking a shady oasis in the desert, this study offers a path towards better asthma control with fewer side effects.

Date :
  1. Date Completed 2008-09-03
  2. Date Revised 2019-11-11
Further Info :

Pubmed ID

18690937

DOI: Digital Object Identifier

10.2174/157488606777934422

Related Literature

Article Analysis
・Effects of ciclesonide oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.